Inmed receives nasdaq delisting notice, and confirms it has filed an appeal and obtained a panel hearing date

Vancouver, british columbia--(newsfile corp. - september 20, 2024) -   inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has timely requested a hearing (the "hearing") before the nasdaq listing qualifications panel (the "panel") to appeal (the "appeal") the determination by the listing qualifications department (the "nasdaq staff") of the nasdaq stock market llc ("nasdaq"), and present its plan to regain and sustain compliance with nasdaq's minimum bid price requirement of at least $1.00 for the continued listing on the nasdaq capital market, as set forth in nasdaq listing rule 5550(a)(2) (the "minimum bid price rule"). nasdaq has notified the company via electronic mail that the hearing has been scheduled for october 31, 2024.
INM Ratings Summary
INM Quant Ranking